Diabetic Patients Alarmed as Abbott Recalls Glucose Monitors Linked to Seven Deaths
Diabetes patients and their families are expressing significant concerns and initiating legal action following Abbott Diabetes Care's recall of glucose monitors associated with seven fatalities. In December, Abbott issued a recall for specific sensors utilized in its FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems, warning that these devices could generate dangerously inaccurate low glucose readings.
Serious Adverse Events and Legal Fallout
The company has documented 736 serious adverse events potentially connected to this malfunction, including 57 incidents within the United States. Among the seven global deaths linked to the equipment is Michael Ford, a 68-year-old resident of Oakland, California, who had Type 2 diabetes. His death occurred after his FreeStyle Libre 3 Plus sensor issued a false low-blood-sugar alert, leading his son and caregiver, Davonte Ford, to administer fast-acting carbohydrates based on the erroneous reading.
Michael Ford's sensor originated from one of the recalled production lots, yet his death is not included in Abbott's official tally, as the specific serial number of his device was not listed in the recall notice. This omission has raised alarms among families and legal experts, who fear that the recall may have overlooked additional affected devices.
Catastrophic Inaccuracy and Tragic Consequences
According to a lawsuit filed by Davonte Ford last month, the reading displayed on his father's monitor that morning was catastrophically inaccurate. As the sensor persistently indicated dangerously low levels, Ford repeatedly provided his father with sugary beverages and snacks. However, when paramedics arrived and measured Michael Ford's blood sugar using their own equipment, they recorded a shocking reading of 551 milligrams per deciliter—more than triple the healthy range.
Michael Ford passed away the following day in a hospital intensive care unit after suffering multiple cardiac arrests. At least three proposed class-action lawsuits have been filed in the United States, including Ford's wrongful death case, with additional legal actions planned in California, Washington, and North Carolina over harms caused by faulty readings.
Patient Experiences and Broader Industry Context
For patients like Angela Ivery, a 71-year-old from Spruce Pine, North Carolina, discovering flaws in these critical devices has been terrifying. She repeatedly visited the emergency room after her Libre 3 sensor falsely indicated low blood sugar, only to find her levels were normal with traditional finger-stick tests. This experience has left her with lasting anxiety and nightmares, causing her to revert to older monitoring methods and avoid social activities.
Continuous glucose monitors, which have revolutionized diabetes care over the past two decades by providing an alternative to frequent finger-stick tests, are not new to recalls. In 2024, Abbott recalled several Libre 3 sensor lots for falsely high readings, while competitor Dexcom recalled hundreds of thousands of monitor receivers in 2016 and 2025 due to audio issues that could lead to missed alerts.
Company Response and Ongoing Investigations
Abbott spokesperson Lindsy Delco stated that the company is deeply saddened by Michael Ford's death and takes all adverse event reports seriously, ensuring each is properly documented and investigated. Delco clarified that the recent problem did not affect every sensor in the impacted lots and that not all reported adverse events are directly linked to the recall. She attributed the incorrect readings to a production line issue that has since been corrected and advised patients experiencing issues to contact Abbott's customer service for assistance.
As legal proceedings advance and patients grapple with the reliability of their essential medical devices, the recall underscores the critical importance of stringent quality control and transparent communication in the healthcare technology sector.
